Is OncoCyte Corp Stock a Good Investment?
OncoCyte Corp Investment Advice | OCX |
- Examine OncoCyte Corp's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research OncoCyte Corp's leadership team and their track record. Good management can help OncoCyte Corp navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact OncoCyte Corp's business and its evolving consumer preferences.
- Compare OncoCyte Corp's performance and market position to its competitors. Analyze how OncoCyte Corp is positioned in terms of product offerings, innovation, and market share.
- Check if OncoCyte Corp pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about OncoCyte Corp's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in OncoCyte Corp stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if OncoCyte Corp is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine OncoCyte Corp Stock
Researching OncoCyte Corp's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 16.0% of the company outstanding shares are owned by corporate insiders. The book value of OncoCyte Corp was now reported as 0.71. The company recorded a loss per share of 4.44. OncoCyte Corp had not issued any dividends in recent years. The entity had 1:20 split on the 25th of July 2023.
To determine if OncoCyte Corp is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding OncoCyte Corp's research are outlined below:
| OncoCyte Corp generated a negative expected return over the last 90 days | |
| OncoCyte Corp has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 1.5 M. Reported Net Loss for the year was (27.78 M) with profit before taxes, overhead, and interest of 188 K. | |
| OncoCyte Corp has about 45.41 M in cash with (23.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. | |
| Roughly 16.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: StockNews.com Initiates Coverage on OncoCyte |
OncoCyte Corp uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in OncoCyte Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to OncoCyte Corp's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact OncoCyte Corp's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises OncoCyte Corp's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-11-12 | 2020-09-30 | -0.09 | -0.1 | -0.01 | 11 | ||
2019-11-14 | 2019-09-30 | -0.09 | -0.1 | -0.01 | 11 | ||
2019-08-14 | 2019-06-30 | -0.09 | -0.1 | -0.01 | 11 | ||
2019-05-14 | 2019-03-31 | -0.09 | -0.08 | 0.01 | 11 | ||
2017-02-27 | 2016-12-31 | -0.1 | -0.11 | -0.01 | 10 | ||
2021-08-10 | 2021-06-30 | -0.1 | -0.12 | -0.02 | 20 | ||
2021-03-16 | 2020-12-31 | -0.11 | -0.09 | 0.02 | 18 | ||
2020-05-12 | 2020-03-31 | -0.11 | -0.13 | -0.02 | 18 |
Know OncoCyte Corp's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as OncoCyte Corp is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading OncoCyte Corp backward and forwards among themselves. OncoCyte Corp's institutional investor refers to the entity that pools money to purchase OncoCyte Corp's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tower Research Capital Llc | 2024-06-30 | 3.1 K | Advisor Group Holdings, Inc. | 2024-06-30 | 1.1 K | Ubs Group Ag | 2024-06-30 | 835 | Bank Of America Corp | 2024-06-30 | 416 | Jpmorgan Chase & Co | 2024-06-30 | 154 | Piscataqua Savings Bank | 2024-09-30 | 25.0 | Coppell Advisory Solutions Llc | 2024-06-30 | 10.0 | Albion Financial Group (utah) | 2024-06-30 | 7.0 | Td Waterhouse Canada Inc | 2024-06-30 | 1.0 | Broadwood Capital Inc | 2024-09-30 | 4.9 M | Awm Investment Company Inc | 2024-09-30 | 1.1 M |
OncoCyte Corp's market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 42.59 M.Market Cap |
|
OncoCyte Corp's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.52) | (1.59) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | (1.09) | (1.14) |
Determining OncoCyte Corp's profitability involves analyzing its financial statements and using various financial metrics to determine if OncoCyte Corp is a good buy. For example, gross profit margin measures OncoCyte Corp's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of OncoCyte Corp's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in OncoCyte Corp's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of OncoCyte Corp. Check OncoCyte Corp's Beneish M Score to see the likelihood of OncoCyte Corp's management manipulating its earnings.
Evaluate OncoCyte Corp's management efficiency
OncoCyte Corp has Return on Asset of (0.1884) % which means that on every $100 spent on assets, it lost $0.1884. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.6532) %, meaning that it generated no profit with money invested by stockholders. OncoCyte Corp's management efficiency ratios could be used to measure how well OncoCyte Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.59 in 2024. Return On Capital Employed is likely to drop to -0.39 in 2024. At this time, OncoCyte Corp's Other Current Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 15.7 M in 2024, whereas Total Assets are likely to drop slightly above 49.1 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.35 | 5.55 | |
| Tangible Book Value Per Share | (4.05) | (3.85) | |
| Enterprise Value Over EBITDA | (0.54) | (0.57) | |
| Price Book Value Ratio | 0.75 | 0.71 | |
| Enterprise Value Multiple | (0.54) | (0.57) | |
| Price Fair Value | 0.75 | 0.71 |
OncoCyte Corp showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 1.002 |
Basic technical analysis of OncoCyte Stock
As of the 27th of November, OncoCyte Corp holds the Risk Adjusted Performance of (0.06), variance of 9.68, and Coefficient Of Variation of (1,152). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of OncoCyte Corp, as well as the relationship between them.OncoCyte Corp's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific OncoCyte Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on OncoCyte Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases OncoCyte Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
OncoCyte Corp's Outstanding Corporate Bonds
OncoCyte Corp issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. OncoCyte Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most OncoCyte bonds can be classified according to their maturity, which is the date when OncoCyte Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US68233JBV52 Corp BondUS68233JBV52 | View | |
| US68233JBU79 Corp BondUS68233JBU79 | View | |
| US68233JBR41 Corp BondUS68233JBR41 | View | |
| US68233JBP84 Corp BondUS68233JBP84 | View | |
| ONCOR ELEC DELIVERY Corp BondUS68233JBG85 | View | |
| ONCOR ELEC DELIVERY Corp BondUS68233JBH68 | View | |
| US68233JBD54 Corp BondUS68233JBD54 | View | |
| ONCOR ELEC DELIVERY Corp BondUS68233JBB98 | View |
Understand OncoCyte Corp's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing OncoCyte Corp's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (28.86) | |||
| Mean Deviation | 2.3 | |||
| Coefficient Of Variation | (1,152) | |||
| Standard Deviation | 3.11 | |||
| Variance | 9.68 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.28) | |||
| Total Risk Alpha | (0.77) | |||
| Treynor Ratio | (28.87) | |||
| Maximum Drawdown | 18.12 | |||
| Value At Risk | (4.76) | |||
| Potential Upside | 4.59 | |||
| Skewness | 0.837 | |||
| Kurtosis | 2.28 |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (28.86) | |||
| Mean Deviation | 2.3 | |||
| Coefficient Of Variation | (1,152) | |||
| Standard Deviation | 3.11 | |||
| Variance | 9.68 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.28) | |||
| Total Risk Alpha | (0.77) | |||
| Treynor Ratio | (28.87) | |||
| Maximum Drawdown | 18.12 | |||
| Value At Risk | (4.76) | |||
| Potential Upside | 4.59 | |||
| Skewness | 0.837 | |||
| Kurtosis | 2.28 |
Consider OncoCyte Corp's intraday indicators
OncoCyte Corp intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of OncoCyte Corp stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
OncoCyte Corp Corporate Filings
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 24th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 22nd of October 2024 Other Reports | ViewVerify |
OncoCyte Stock media impact
Far too much social signal, news, headlines, and media speculation about OncoCyte Corp that are available to investors today. That information is available publicly through OncoCyte media outlets and privately through word of mouth or via OncoCyte internal channels. However, regardless of the origin, that massive amount of OncoCyte data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of OncoCyte Corp news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of OncoCyte Corp relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to OncoCyte Corp's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive OncoCyte Corp alpha.
OncoCyte Corp Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards OncoCyte Corp can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
OncoCyte Corp Corporate Management
| Andrea James | Chief Officer | Profile | |
| Ekkehard MD | Chief Officer | Profile | |
| Joshua Riggs | Interim Officer | Profile | |
| Tony Kalajian | Senior Vice President Chief Accounting Officer | Profile | |
| Andrew Last | Independent Director | Profile |
Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.